(Q38466779)

3 September 2017

title

Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis (English)

1 reference

3 September 2017

1 reference

Partin AW

1

1 reference

3 September 2017

Catalona WJ

2

1 reference

3 September 2017

Finlay JA

3

1 reference

3 September 2017

Darte C

4

1 reference

3 September 2017

Tindall DJ

5

1 reference

3 September 2017

Young CY

6

1 reference

3 September 2017

Klee GG

7

1 reference

3 September 2017

Chan DW

8

1 reference

3 September 2017

Rittenhouse HG

9

1 reference

3 September 2017

Wolfert RL

10

1 reference

3 September 2017

Woodrum DL

11

1 reference

3 September 2017

language of work or name

English

0 references

publication date

1 November 1999

1 reference

3 September 2017

1 reference

3 September 2017

volume

54

1 reference

3 September 2017

issue

5

1 reference

3 September 2017

page(s)

839-845

1 reference

Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900270-8

7 January 2021

Screening for Prostatic Carcinoma with Prostate Specific Antigen: Results of the Second Year

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900270-8

7 January 2021

Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900270-8

7 January 2021

Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900270-8

7 January 2021

Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900270-8

7 January 2021

Serum Prostate Specific Antigen Complexed toα1-Antichymotrypsin as an Indicator of Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900270-8

7 January 2021

Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900270-8

7 January 2021

Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900270-8

7 January 2021

Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900270-8

7 January 2021

Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900270-8

7 January 2021

Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/mL total PSA

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900270-8

7 January 2021

Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900270-8

7 January 2021

Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900270-8

7 January 2021

Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900270-8

7 January 2021

Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900270-8

7 January 2021

Development of monoclonal antibodies specific for human glandular kallikrein (hK2): development of a dual antibody immunoassay for hK2 with negligible prostate-specific antigen cross-reactivity

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900270-8

7 January 2021

Human glandular kallikrein, hK2, shows arginine-restricted specificity and forms complexes with plasma protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900270-8

7 January 2021

Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900270-8

7 January 2021

Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900270-8

7 January 2021

In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900270-8

7 January 2021

10.1016/S0090-4295(99)00270-8

Identifiers

DOI

1 reference

3 September 2017

1 reference